<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Srinivasa S</submitter><funding>National Center for Advancing Translational Sciences</funding><funding>National Center for Research Resources</funding><funding>National Institutes of Health</funding><funding>Harvard Catalyst</funding><pagination>bvab175</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8664688</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(1)</volume><pubmed_abstract>Subclinical myocardial dysfunction is prevalent among well-treated persons with HIV (PWH). We have previously demonstrated unique renin-angiotensin-aldosterone system physiology among PWH with metabolic dysregulation. Mineralocorticoid receptor blockade may be a targeted treatment strategy for subclinical heart disease in PWH. Forty-six PWH were randomized to receive either eplerenone 50 mg daily or placebo in a 6-month randomized, double-blinded, placebo-controlled trial. We assessed changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of cardiac stretch, under controlled posture and dietary conditions. The eplerenone- and placebo-treated groups demonstrated a long duration of HIV with good immunological control. NT-proBNP levels were similar between the groups at</pubmed_abstract><journal>Journal of the Endocrine Society</journal><pubmed_title>Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV.</pubmed_title><pmcid>PMC8664688</pmcid><funding_grant_id>R01 HL15129</funding_grant_id><funding_grant_id>R01 DK49302</funding_grant_id><funding_grant_id>UL1 RR025758</funding_grant_id><funding_grant_id>UL1 TR001102</funding_grant_id><funding_grant_id>P30 DK040561</funding_grant_id><funding_grant_id>K24 HL103845</funding_grant_id><funding_grant_id>K23 HL136262</funding_grant_id><funding_grant_id>UL1 TR000170</funding_grant_id><pubmed_authors>Fitch KV</pubmed_authors><pubmed_authors>Srinivasa S</pubmed_authors><pubmed_authors>Adler GK</pubmed_authors><pubmed_authors>Thomas TS</pubmed_authors><pubmed_authors>deFilippi C</pubmed_authors><pubmed_authors>Iyengar S</pubmed_authors><pubmed_authors>Burdo TH</pubmed_authors><pubmed_authors>Walpert AR</pubmed_authors><pubmed_authors>Grinspoon SK</pubmed_authors><pubmed_authors>Shen G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluation of Mineralocorticoid Receptor Antagonism on Changes in NT-proBNP Among Persons With HIV.</name><description>Subclinical myocardial dysfunction is prevalent among well-treated persons with HIV (PWH). We have previously demonstrated unique renin-angiotensin-aldosterone system physiology among PWH with metabolic dysregulation. Mineralocorticoid receptor blockade may be a targeted treatment strategy for subclinical heart disease in PWH. Forty-six PWH were randomized to receive either eplerenone 50 mg daily or placebo in a 6-month randomized, double-blinded, placebo-controlled trial. We assessed changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker of cardiac stretch, under controlled posture and dietary conditions. The eplerenone- and placebo-treated groups demonstrated a long duration of HIV with good immunological control. NT-proBNP levels were similar between the groups at</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-26T03:57:51.304Z</modification><creation>2022-02-11T14:05:27.349Z</creation></dates><accession>S-EPMC8664688</accession><cross_references><pubmed>34909518</pubmed><doi>10.1210/jendso/bvab175</doi></cross_references></HashMap>